Learn about the latest treatments for advanced ovarian cancer. We’ve got it covered, from new FDA approvals to emerging approaches in immunotherapy, targeted therapy, cancer vaccines, drug combinations, antibody-drug conjugates, and more.

  • February 2, 2021  

    How an Expert Would Manage Her Own Advanced Ovarian Cancer

    With: Summer Dewdney, MD

    Cancer patients often ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks oncologist Summer Dewdney, MD, how she would handle her own diagnosis of advanced ovarian cancer. Dr. Dewdney is Director of the Division of Gynecologic Oncology at Rush University Medical Center in Chicago, Illinois. Curious Dr. George: You are an expert clinical oncologist treating patients… Read more »

  • February 18, 2022  

    Chemotherapy: Before Surgery Vs. After Surgery Bookmark

    George Lundberg, MD

    According to this article from the Cochrane Database of Systematic Reviews, chemotherapy administered before surgery may be beneficial for people with advanced ovarian cancer.

    .

  • February 18, 2022  

    This New Ovarian Cancer Treatment Could Improve Survival Rates Bookmark

    George Lundberg, MD

    Recently approved by the U.S. Food and Drug Administration (FDA), the drug Cytalux is given to ovarian cancer patients to allow surgeons to recognize cancer cells more clearly, promoting more complete surgical removal of tumors. Learn more in this story from The Philadelphia Inquirer.

    .

    • SEE ALL
Sincere thanks to Cancer Commons and their Virtual Tumor Board for their comprehensive analysis and recommendations regarding treatments for my pancreatic cancer. I feel fortunate to have the benefit of the expertise offered by their board of scientists, researchers, physicians, and experts in this field.

Roy Saenz

Molecular tests help match patients to the personalized treatments that are most likely to work for them. Keep up with new developments in genetic tests, blood tests, liquid biopsies, tumor mutations, other biomarkers, precision medicine, and next-generation sequencing.

Some of the most promising new treatments for advanced ovarian cancer are currently being tested in patients enrolled in clinical trials. We help you stay up to date on the latest results from these studies.

  • July 28, 2021  

    ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer Bookmark

    George Lundberg, MD

    As reported by Cancer Network, new results from a phase 3 clinical trial testing the drug rucaparib (Rubraca), which has already been approved by the U.S. Food and Drug Administration, show that it prolongs progression-free survival in some patients with advanced ovarian cancer.

    .

  • April 12, 2021  

    Long-Term Survival Data for Olaparib Maintenance in Ovarian Cancer Show Clinically Meaningful Boost Bookmark

    George Lundberg, MD

    Cancer Network reports results from 5 years of follow up for a clinical trial in which the drug olaparib (Lynparza) was given to people who had already been treated for relapsed, high-grade serous, or endometrioid ovarian cancer—including primary peritoneal or fallopian tube cancer. Overall survival data show that olaparib outperformed a placebo drug for these patients, suggesting the possibility that it could be an effective “maintenance therapy.”

    .

    • SEE ALL
This free-of-charge, high-quality information service is a wonderful resource for patients with advanced cancer.

Hope S. Rugo, MD
UCSF Comprehensive Cancer Center

Cancer affects many aspects of life, whether you’re newly diagnosed, in the midst of treatment, or in follow-up care. Learn about ways to maintain quality of life, such as palliative care and managing side effects.

You’re not alone. Read how other patients and caregivers navigated diagnosis, treatment, and life with cancer. We hope their stories provide insights and hope for your own cancer journey.

More patient stories

Learn more about what’s new in advanced cancer research and treatment, including screening and statistics, using artificial intelligence to improve treatment, and other new horizons in cancer care.

  • April 13, 2022  

    Cancer Commons Adapts to Remain True to Our Mission

    With: Shelley Frisbie

    People facing advanced cancer come to Cancer Commons to ensure they have all the information they need to make their best-possible cancer care decisions. Here, Curious Dr. George asks our CFO & COO Shelley Frisbie about recent updates to our organization. Curious Dr. George: You have been the CFO of Cancer Commons for some time and recently added the COO title and duties to… Read more »

  • March 16, 2022  

    Cellular Aging and the Development of Cancer

    With: Kaumudi Bhawe, PhD

    Cancer is so often a disease of older people that a whole medical field, “oncogeriatrics,” exists to address the topic. Deeper understanding of the links between cancer and aging could lead to better treatments. Here, our Curious Dr. George asks Cancer Commons Clinical Scientist Kaumudi Bhawe, PhD, about the relationship between cancer and aging processes that occur in individual cells in our bodies—throughout our… Read more »

    • SEE ALL

The coronavirus pandemic presents unprecedented challenges to cancer patients. We can help you understand how COVID-19 might impact your treatment and other aspects of your cancer care.